Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma

Gal Markel, Tali Cohen-Sinai, Michal J. Besser, Kfir Oved, Orit Itzhaki, Rachel Seidman, Avraham J. Treves, Eduard Fridman, Yona Keisari, Zohar Dotan, Jacob Ramon, Jacob Schachter*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: Interleukin-2 (IL-2) shows encouraging clinical results in metastatic renal cell carcinoma (RCC) patients, but is limited by substantial toxicity. Cell-based therapy holds a promise, but past attempts in RCC were unsuccessful. Advances in tumor-infiltrating lymphocytes (TIL) generation technology and modified clinical protocols recently yielded a 50% response in refractory melanoma patients. Materials and Methods: RCC-derived TIL and tumor cells were processed by current protocols from tumor specimens in a clean laboratory. The expanded TIL were characterized and tested in functional assays. Results: The TIL cultures were efficiently generated and massively expanded. Virtually all the expanded cells were T-cells, but a considerable variability in the CD4/CD8 ratio and a frequent CD4 -CD8 - phenotype were observed. The TIL exerted cytotoxic or IFNγ-release activities against autologous targets in major histocompatibility (MHC) class I-restricted and -independent functional patterns. The functional results were superior to former technologies. Conclusion: Recent developments in TIL generation technology and clinical patient conditioning protocols indicate that the TIL-based approach for RCC could be revisited.

Original languageEnglish
Pages (from-to)145-154
Number of pages10
JournalAnticancer Research
Issue number1
StatePublished - Jan 2009


  • Adoptive cell transfer
  • Immunotherapy
  • T-cells


Dive into the research topics of 'Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this